^
    CANCER:

    Rhabdomyosarcoma





    Show legend
    Group by Gene:
    Include preclinical:

    0
    Topoisomerase I inhibitor
    topotecan
    irinotecan
    1
    Topoisomerase II inhibitor, RNA synthesis inhibitor
    dactinomycin
    2
    Alkylating agent, DNA inhibitor
    trabectedin
    3
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
    methotrexate
    4
    Mitosis inhibitor
    vinorelbine
    5
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    6
    Alkylating agent, Tubulin polymerization inhibitor
    cyclophosphamide + vinorelbine tartrate
    7
    Bifunctional alkylating agent, Topoisomerase II inhibitor
    doxorubicin hydrochloride + ifosfamide
    8
    Bifunctional alkylating agent, Topoisomerase II inhibitor, Tubulin polymerization inhibitor
    doxorubicin hydrochloride + ifosfamide + vincristine
    9
    PD1 inhibitor
    nivolumab
    10
    T-lymphocyte cell therapy
    T-lymphocyte cell therapy
    11
    Chemotherapy
    VAC
    IE
    12
    Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA inhibitor
    carboplatin + etoposide oral
    13
    Alkylating agent, Topoisomerase I inhibitor
    cyclophosphamide + topotecan
    14
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor, RNA synthesis inhibitor
    vincristine + dactinomycin
    15
    Tubulin polymerization inhibitor, DNA synthesis inhibitor, Topoisomerase I inhibitor
    temozolomide + irinotecan + vincristine
    16
    Bifunctional alkylating agent, Topoisomerase II inhibitor, Alkylating agent, Tubulin polymerization inhibitor
    doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
    17
    Topoisomerase II inhibitor, Alkylating agent, Tubulin polymerization inhibitor
    doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
    18
    Tubulin polymerization inhibitor, Topoisomerase I inhibitor
    irinotecan + vincristine
    19
    MEK inhibitor, IGF-1R inhibitor
    trametinib + AMG 479
    20
    XPO1 inhibitor, CDK9 inhibitor, P-TEFb inhibitor
    selinexor + VIP152
    21
    Proteasome inhibitor, CDK9 inhibitor, P-TEFb inhibitor
    bortezomib + VIP152
    carfilzomib + VIP152
    22
    CDK9 inhibitor, P-TEFb inhibitor
    VIP152
    23
    FGFR4 inhibitor
    ABSK012
    24
    Multi-tyrosine kinase inhibitor
    anlotinib
    pazopanib
    25
    ALK inhibitor
    crizotinib
    26
    CXCL12 inhibitor, Farnesyl transferase inhibitor
    tipifarnib
    27
    LSD1 inhibitor
    SP2577
    28
    HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
    entinostat
    29
    CXCL12 inhibitor, Farnesyl transferase inhibitor, MEK inhibitor
    trametinib + tipifarnib
    No biomarker
    PD-L1 expression
    EWSR1-TFCP2 fusion
    HRAS mutation
    KDM1A overexpression
    PAX3-FOXO1 fusion
    HER-2 expression
    RAS mutation
    MYCN amplification
    FGFR4 V550L
    BRAF-MAD1L1 fusion